mercredi 1 octobre 2014

Leaky gut and auto-immune diseases

http://www.thepaleomom.com/2014/09/comes-first-leaky-gut-dysfunctional-immune-system.html

Une démonstration de l'ignorance scientifique sur les sucres

http://www.passeportsante.net/fr/Actualites/Dossiers/DossierComplexe.aspx?doc=mincir-index-glycemique-l-index-glycemique-une-question-de-digestibilite-

Notamment là:
http://www.passeportsante.net/fr/Actualites/Dossiers/DossierComplexe.aspx?doc=mincir-index-glycemique-index-glycemique-des-fruits-difficile-de-s-y-retrouver
Uui si on n'explique pas la charge glycémique on ne comprend rien. What else?

La prévention des maladies cardiovasculaires dans l'impasse des incantations

http://sante.lefigaro.fr/actualite/2014/09/29/22838-80-dinfarctus-moins-avec-bonne-hygiene-vie

http://content.onlinejacc.org/article.aspx?articleID=1909605

Full-size image (42 K)
A very impressive prevention: MI Incidence for the Addition of Any Low-Risk Behavior
Age-standardized incidence rates and multivariable-adjusted relative risks of MI for the addition of any single low-risk factor compared with the high-risk group for men without hypertension and high cholesterol (n = 20,721), p for trend < 0.001 (A), and men with hypertension and high cholesterol (n = 7,139), p for trend = 0.002 (3 and 4 statistically significantly lower than the reference) (B). CI = confidence interval; MI = myocardial infarction; RR = relative risk.

Multifactorial disease and multitarget prevention



mardi 30 septembre 2014

Lipoproteins and prediction of CVD, CHD and stroke

Full-size image (47 K)
ApoB reduction and risk of CVD, CHD and stroke
http://www.sciencedirect.com/science/article/pii/S0002914912017158







Current Opinion in Endocrinology, Diabetes & Obesity:
doi: 10.1097/MED.0b013e32835ed9cb
LIPIDS: Edited by Annabelle Rodriguez

Update on the detection and treatment of atherogenic low-density lipoproteins

Sniderman, Allana; Kwiterovich, Peter O.b

Collapse Box

Abstract

Purpose of review: To explain why epidemiological studies have reached such diverse views as to whether apolipoprotein B (apoB) and/or low-density lipoprotein particle number (LDL-P) are more accurate markers of the risk of cardiovascular disease than LDL-C or non-high-density lipoprotein cholesterol (HDL-C) and to review the treatment options to lower LDL.
Recent findings: The Emerging Risk Factor Collaboration, a large prospective participant level analysis, a meta-analysis of statin clinical trials, and the Heart Protection Study have each reported that apoB does not add significantly to the cholesterol markers as indices of cardiovascular risk. By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. As well, three studies using discordance analysis each demonstrated that apoB and LDL-P were superior to the cholesterol markers. Two approaches to resolve these differences are brought to bear in this article: first, which results are credible and second, how does taking the known differences in LDL composition into account, help resolve them. The best identification of individuals at risk of coronary artery disease or with coronary artery disease allows the most efficacious treatment of elevated LDL-P and will permit a more extensive use of some of the more novel LDL-lowering agents.
Summary: Much of the controversy vanishes once the physiologically driven differences in the composition of the apoB lipoprotein particles are taken into account, illustrating that epidemiology, not directed by physiology, is like shooting without aiming.

Saturated fats and lipid profile

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916209/

And the combined effect of med diet and weight loss

http://atvb.ahajournals.org/content/34/2/433.long






Current Opinion in Lipidology:
doi: 10.1097/MOL.0b013e3283613ba2
LIPID METABOLISM: Edited by Ernst J. Schaefer

Dietary fatty acids and lipoprotein metabolism: new insights and updates

Ooi, Esther M.M.a; Ng, Theodore W.K.a; Watts, Gerald F.a; Barrett, P. Hugh R.a,b

Collapse Box

Abstract

Purpose of review: Dyslipidemia is a powerful risk factor for cardiovascular disease (CVD). Dietary fatty acid composition regulates lipids and lipoprotein metabolism and may confer CVD benefit. This review updates understanding of the effect of dietary fatty acids on lipoprotein metabolism in humans.
Recent findings: High dietary fish-derived n-3 polyunsaturated fatty acid (PUFA) consumption diminished hepatic triglyceride-rich lipoprotein (TRL) secretion and enhanced TRL to LDL conversion. n-3 PUFA also decreased TRL-apoB-48 concentration by decreasing TRL-apoB-48 secretion. High n-6 PUFA intake decreased liver fat, and plasma proprotein convertase subtilisin/kexin type 9, triglycerides, total-cholesterol and LDL-cholesterol concentrations. Intake of saturated fatty acids with increased palmitic acid at the sn-2 position was associated with decreased postprandial lipemia, which might be due to decreased triglyceride absorption. Replacing carbohydrate with monounsaturated fatty acids increased TRL catabolism. Ruminant trans-fatty acid decreased HDL cholesterol, but the mechanisms are unknown. A new role for APOE genotype in regulating lipid responses was also described.
Summary: The major advances in understanding the effect of dietary fatty acids on lipoprotein metabolism have focused on n-3 PUFA. This knowledge provides insights into the importance of regulating lipoprotein metabolism as a mode to improve plasma lipids and potential CVD risk. Further studies are required to better understand the cardiometabolic effects of other dietary fatty acids.

Fermented raw milk improves your lipid profile

http://ajcn.nutrition.org/content/36/6/1106.full.pdf+html

Lipid profile and lifestyle in healthy men

https://www.jstage.jst.go.jp/article/jcbn/54/3/54_13-78/_pdf


The shift toward an atherogenic profile is correlated with increased BMI and moderately with age. But one must keep in mind that lipid profile is neither the only risk factor of CVD and nor the most predictive...